TIMES OF ORAL SUPPLEMENTATION IN THE TREATMENT OF ARIPIPRAZOLE LONG-ACTING INJECTABLE IN STANDARD CLINICAL PRACTICE
Poster A104, Monday, October 8, 11:30 am - 1:00 pm, Essex Ballroom
Sergio Sanchez Alonso1, Laura Mata1, Raquel Álvarez2, Santiago Ovejero1; 1Departamento de Psiquiatría. Hospital Universitario Fundación Jiménez Díaz. Madrid, 2Departamento de Psiquiatría. Hospital Universitario Rey Juan Carlos. Móstoles
Background: The aim of this study is to analyze the different patterns of oral supplementation in the use of aripiprazole LAI. Methods: The sample consists of 72 patients treated with aripiprazole LAI. We measure oral supplementation time by gender, diagnosis, previous oral dose of aripiprazole, years of illness evolution and the place of treatment start. Results: The average days of oral supplementation is 109.61 days. The percentage of patients with 15 or less days of supplementation is 47.2% (N=34). Patients with previous oral dose of aripiprazole ≤20 mg required shorter times of oral supplementation (59.6% (N=31) ≤15 days). Patients with previous doses between 20-30 mg need longer periods of supplementation (75% (N=9)) >15 days). In contrast, 100% (N=8) patients with oral doses above 30 mg needed overlap periods longer than 15 days. These results showed statistically significant differences (p=0.02). Time of oral supplementation is lower in patients that starts aripiprazole LAI at Outpatient Unit (55.8% (N=29) ≤15 days) than patients that start treatment at Impatient Unit (75% (N=15) >15 days). These results were statistically significant (p=0.019). Discussion: Less than half of patients observed in this sample show overlap periods of <15 days. Patients with previous oral aripiprazole doses >15 mg tend to require more than 15 days of oral suplementation. Patients with >30 mg always require supplementation times above 15 days. Most of the patients that starts aripiprazole LAI at Inpatient Unit need longer periods of oral supplementation.
Topic Area: Psychopharmacology